7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A clinical-level guide to recognizing, preventing, and managing adverse events with SGLT2 inhibitors, covering DKA, UTIs, genital mycotic infections, volume depletion, and limb amputation risk, with inline citations to primary sources.
A complete MD/PharmD-level guide to SGLT2 inhibitor billing codes, prior-authorization requirements, step-therapy rules, and appeals strategy for empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.
Clinician-facing SGLT2 inhibitor DDI reference table covering empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin with insulin, diuretics, lithium, digoxin, and more.
A clinical-grade monitoring bundle for SGLT2 inhibitors covering baseline workup, ongoing labs, safety signals, dose adjustments, and stopping rules, written at MD/PharmD level.
A prescriber-level summary of SGLT2 inhibitor use across special populations: heart failure, CKD, elderly patients, pregnancy, and more. Includes trial data, dosing guidance, and safety considerations.
A clinician-level guide to SGLT2 inhibitor initiation, dose titration, and safe tapering. Covers empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin with evidence from EMPA-REG OUTCOME, DAPA-HF, CREDENCE, and current ADA/ACC guidelines.
Evidence-based guide to choosing between empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and sotagliflozin based on indication, trial data, renal function, and formulary access.